SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cell Therapeutics (CTIC)
CTIC 9.0900.0%Jun 26 5:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who wrote (801)2/16/2006 3:55:21 AM
From: Icebrg  Read Replies (1) of 946
 
Peter,

The only data available on Xyotax vs. control, that I have seen was presented by Dr. Socinski at last year's Chemotherapy Foundation Symposium.

The aggregated results for woman from Stellar 3 and 4 as per Dr Socinski's presentation were:

              n     Median Survival 
<55 years  
Xyotax       28        10,0     
Control      22         5,2 

> 55 years      
Xyotax       69         8,9   
Control      79         8,6


Cancerconsultants made the following summary of what was presented at the conference:

* Median overall survival among women with high estradiol levels was 300 days for those on the Xyotax arm, compared with only 167 days for those on the Paraplatin/Taxol arm (p=0.039) in the STELLAR 3 trial.

* Median overall survival among all women in a combined analysis of the STELLAR 3 and STELLAR 4 trials indicates an improvement in survival of approximately two months in women treated with Xyotax compared to either chemotherapy regimen (9.4 months versus 7.7 months, respectively, p=0.03); however, it appears that this remains significant only in women under the age of 55 years

* Women under the age of 55 years had a significantly improved survival on the Xyotax arms compared to the chemotherapy arms (10.0 months versus 5.2 months, p=0.038)

* Survival at one year among all women in a combined analysis of the STELLAR 3 and 4 trials was 40% for women treated with Xyotax, compared with 25% for women treated with chemotherapy

* There was no difference in survival between Xyotax or chemotherapy in men included in these trials

* Xyotax was associated with a significant reduction in toxicities compared to either chemotherapy regimen

professional.cancerconsultants.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News